202 related articles for article (PubMed ID: 28631775)
21. Treatment of Recurrent Epithelial Ovarian Cancer.
Claussen C; Rody A; Hanker L
Geburtshilfe Frauenheilkd; 2020 Dec; 80(12):1195-1204. PubMed ID: 33293727
[TBL] [Abstract][Full Text] [Related]
22. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Pujade-Lauraine E; Hilpert F; Weber B; Reuss A; Poveda A; Kristensen G; Sorio R; Vergote I; Witteveen P; Bamias A; Pereira D; Wimberger P; Oaknin A; Mirza MR; Follana P; Bollag D; Ray-Coquard I
J Clin Oncol; 2014 May; 32(13):1302-8. PubMed ID: 24637997
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of trabectedin plus pegylated liposomal doxorubicin for the treatment of women with relapsed platinum-sensitive ovarian cancer in the UK: analysis based on the final survival data of the OVA-301 trial.
Fisher M; Gore M
Value Health; 2013 Jun; 16(4):507-16. PubMed ID: 23796284
[TBL] [Abstract][Full Text] [Related]
24. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
Thigpen T; Vance R; Puneky L; Khansur T
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
[TBL] [Abstract][Full Text] [Related]
25. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
[TBL] [Abstract][Full Text] [Related]
26. Use of pegylated liposomal doxorubicin in the management of platinum-sensitive recurrent ovarian cancer: current concepts.
Rakowski JA; Ahmad S; Holloway RW
Expert Rev Anticancer Ther; 2012 Jan; 12(1):31-40. PubMed ID: 22149430
[TBL] [Abstract][Full Text] [Related]
27. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
[TBL] [Abstract][Full Text] [Related]
28. Gynecological malignancies.
Schaebler DL; Schilder RJ; Young RC
Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
[TBL] [Abstract][Full Text] [Related]
29. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
Mirza MR; Monk BJ; Herrstedt J; Oza AM; Mahner S; Redondo A; Fabbro M; Ledermann JA; Lorusso D; Vergote I; Ben-Baruch NE; Marth C; Mądry R; Christensen RD; Berek JS; Dørum A; Tinker AV; du Bois A; González-Martín A; Follana P; Benigno B; Rosenberg P; Gilbert L; Rimel BJ; Buscema J; Balser JP; Agarwal S; Matulonis UA;
N Engl J Med; 2016 Dec; 375(22):2154-2164. PubMed ID: 27717299
[TBL] [Abstract][Full Text] [Related]
30. Epithelial ovarian cancer: Evolution of management in the era of precision medicine.
Lheureux S; Braunstein M; Oza AM
CA Cancer J Clin; 2019 Jul; 69(4):280-304. PubMed ID: 31099893
[TBL] [Abstract][Full Text] [Related]
31. The Evolving Landscape of Chemotherapy in Newly Diagnosed Advanced Epithelial Ovarian Cancer.
Monk BJ; Randall LM; Grisham RN
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e141-e151. PubMed ID: 31099631
[TBL] [Abstract][Full Text] [Related]
32. Treatment goals in ovarian cancer.
Ozols RF
Int J Gynecol Cancer; 2005; 15 Suppl 1():3-11. PubMed ID: 15839952
[TBL] [Abstract][Full Text] [Related]
33. Front-Line Maintenance Therapy in Advanced Ovarian Cancer-Current Advances and Perspectives.
Reverdy T; Sajous C; Péron J; Glehen O; Bakrin N; Gertych W; Lopez J; You B; Freyer G
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32854393
[TBL] [Abstract][Full Text] [Related]
34. Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer.
Walter A; Rocconi RP; Monk BJ; Herzog TJ; Manning L; Bognar E; Wallraven G; Aaron P; Horvath S; Tang M; Stanbery L; Coleman RL; Nemunaitis J
Gynecol Oncol; 2021 Dec; 163(3):459-464. PubMed ID: 34702567
[TBL] [Abstract][Full Text] [Related]
35. New Therapies for Ovarian Cancer.
O'Malley DM
J Natl Compr Canc Netw; 2019 May; 17(5.5):619-621. PubMed ID: 31117037
[TBL] [Abstract][Full Text] [Related]
36. Ovarian cancer: Current status and strategies for improving therapeutic outcomes.
Chandra A; Pius C; Nabeel M; Nair M; Vishwanatha JK; Ahmad S; Basha R
Cancer Med; 2019 Nov; 8(16):7018-7031. PubMed ID: 31560828
[TBL] [Abstract][Full Text] [Related]
37. Ovarian cancer: Novel molecular aspects for clinical assessment.
Palmirotta R; Silvestris E; D'Oronzo S; Cardascia A; Silvestris F
Crit Rev Oncol Hematol; 2017 Sep; 117():12-29. PubMed ID: 28807232
[TBL] [Abstract][Full Text] [Related]
38. [Position of targeted therapy in ovarian cancer management].
Majirský M; Kubecová M; Kindlová E; Tikovský K
Ceska Gynekol; 2013 Aug; 78(4):347-50. PubMed ID: 24040982
[TBL] [Abstract][Full Text] [Related]
39. Targeted therapies: New standard for relapsed ALL.
Hutchinson L
Nat Rev Clin Oncol; 2017 May; 14(5):264. PubMed ID: 28322244
[No Abstract] [Full Text] [Related]
40. Rationale for the Use of Homologous Recombination Proficient Molecular Profile as a Biomarker for Therapeutic Targeting in Ovarian Cancer.
Nemunaitis J; Stanbery L; Walter A; Rocconi R; Stephens P
Oncol Rev; 2023; 17():11471. PubMed ID: 37799595
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
